Medipharm Labs Corp (TO:LABS) — Market Cap & Net Worth
Market Cap & Net Worth: Medipharm Labs Corp (LABS)
Medipharm Labs Corp (TO:LABS) has a market capitalization of $23.05 Million (CA$31.86 Million) as of June 17, 2026. Listed on the TO stock exchange, this Canada-based company holds position #24670 globally and #951 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medipharm Labs Corp's stock price CA$0.08 by its total outstanding shares 424864269 (424.86 Million). Review LABS total liabilities to assess the company's total debt and financial obligations.
Medipharm Labs Corp Market Cap History: 2018 to 2026
Medipharm Labs Corp's market capitalization history from 2018 to 2026. Data shows change from $534.77 Million to $23.05 Million (-14.05% CAGR).
Medipharm Labs Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medipharm Labs Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.44x
Medipharm Labs Corp's market cap is 0.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $534.77 Million | $10.20 Million | -$8.41 Million | 52.44x | N/A |
| 2019 | $1.19 Billion | $129.25 Million | $1.13 Million | 9.18x | 1048.92x |
| 2020 | $162.89 Million | $36.01 Million | -$67.11 Million | 4.52x | N/A |
| 2021 | $56.86 Million | $21.71 Million | -$54.80 Million | 2.62x | N/A |
| 2022 | $21.51 Million | $22.12 Million | -$29.98 Million | 0.97x | N/A |
| 2023 | $19.98 Million | $33.06 Million | -$13.08 Million | 0.60x | N/A |
| 2024 | $18.44 Million | $41.96 Million | -$10.69 Million | 0.44x | N/A |
| 2025 | $19.98 Million | $45.12 Million | -$8.27 Million | 0.44x | N/A |
Competitor Companies of LABS by Market Capitalization
Companies near Medipharm Labs Corp in the global market cap rankings as of June 17, 2026.
Key companies related to Medipharm Labs Corp by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Medipharm Labs Corp Historical Marketcap From 2018 to 2026
Between 2018 and today, Medipharm Labs Corp's market cap moved from $534.77 Million to $ 23.05 Million, with a yearly change of -14.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$23.05 Million | +15.38% |
| 2025 | CA$19.98 Million | +8.33% |
| 2024 | CA$18.44 Million | -7.69% |
| 2023 | CA$19.98 Million | -7.14% |
| 2022 | CA$21.51 Million | -62.16% |
| 2021 | CA$56.86 Million | -65.09% |
| 2020 | CA$162.89 Million | -86.27% |
| 2019 | CA$1.19 Billion | +121.84% |
| 2018 | CA$534.77 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Medipharm Labs Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.05 Million USD |
| MoneyControl | $23.05 Million USD |
| MarketWatch | $23.05 Million USD |
| marketcap.company | $23.05 Million USD |
| Reuters | $23.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medipharm Labs Corp
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It a… Read more